...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews

"Anything catch your eye as revelatory above the already known, Bear?"

No. It was a well written review of the bromodomain biology of BET inhibitor field, written by 3 Resverlogix employees. However, as Cityslicker wrote earlier "This review is useful as a convenient collation of publications, but I would say it is superficial in its treatment of the literature and offers nothing new." However, for those not as familiar with apabetalone, BET inhibition and bromodomain biology, this is a great introduction to those areas.

BDAZ

Share
New Message
Please login to post a reply